Trend Following/Kelly Criterion {Little Fire Capital Management} (Not Financial Advice) Financial amoeba Meme Dev for $CHADSLIME and $QNT M@XI ๐๐๐๐ข๐ข
Researchers used CRISPR gene editing to identify a DNA enhancer called HRRINT3 that helps the androgen receptor suppress tumor growth in estrogen receptor-positive breast cancer by regulating gene activity and restraining cell division.
https://t.co/mpGbz8XLWj
We may have a cure for Alzheimerโs ๐คฏ
Researchers have fully reversed advanced Alzheimerโs in animal experiments
Researchers from Case Western and University hospitals published a paper that proves advanced Alzheimerโs can actually be reversed.
And they achieved full neurological recovery.
Here is how they did it:
they realized the damaged brain was basically losing its energy balance.
so they used a drug called p7c3-a20 on mice with advanced alzheimer's to restore their nad+ homeostasis (the molecule that gives cells energy and repairs daily damage).
And the results are actually mindblowing..
- the mice fully regained their memory and learning abilities
- the drug physically repaired the blood-brain barrier and closed structural gaps
- it stopped dna damage, oxidative stress, and neuroinflammation
- it literally reversed the toxic tau proteins in the brain
when they tested the mice in memory mazes, the treated ones performed exactly like completely healthy mice. the brain actually repaired itself.
and the craziest part?
this isn't just a mouse thing.. the researchers mapped the brain and found 46 specific proteins that normalized in the mice, and identified those exact same therapeutic targets in human alzheimer's brains.
this means the foundation is officially laid to translate this directly to human patient care.
New Stifel report highlights the $400B pharma patent cliff/$1.5T in M&A firepower & the evolution to more โ$50B drugs at medium prices.โ Therapeutic areas that could yield those opportunities: CNS/neuropsychiatry & cardio at the top after obesity/diabetes. Nice snapshot of stated priorities of top biopharma acquirers & the broadening acquirer base (prob even broader now that โcuringโ disease is the next frontier of AI companies). Will link to @TimOpler full report when itโs out. $XBI $BBC $IBB
Why does immunotherapy work in MSI-H but rarely in MSS colorectal cancer?
A new Science paper offers an interesting clue: in patient tumors, MSI-H cancers have more Th1-like CD4+ T cells that help drive antitumor immunity, while MSS tumors have more suppressive Tregs.
In MSS mouse models, adding an OX40 agonist to anti-PD-1 improved tumor control and survival.
Still preclinical, but could targeting CD4+ T cells help overcome immunotherapy resistance in MSS colorectal cancer?
@ScienceMagazine
Pharmaceutical companies are among the largest, most profitable, and most strategically important businesses in the world.
The top 30 pharma companies represent roughly $5T of market cap. Eli Lilly alone has a market capitalization of over $1T, putting it in a club historically dominated by tech darlings.
In Q3 2026 alone, Lilly's GLP-1 portfolio did close to $17B, nearly matching Anthropic's revenue in that quarter. Analysts expect Lilly's GLP-1 portfolio to grow to over $100B in annual sales by 2030.
Big Pharma Can Rival Big Software: https://t.co/A96FDSSk57
Do you know how sad it is that we need months and mice to find even one of these compounds? And then the biology may not ever reach a clinical trial and fails 97% of the time?
The ability to test a compound is so severely lacking that we have to use mice and assume theyโre humans and we are lucky if that assumption is correct in clinical trials. we have no idea how we are wrong when itโs not correct.
Rapamycin was SO hyped for longevity. Itโs a miracle drug! For a mouse! But it didnโt work in humans.
We need hyperscaled testing infrastructure that discovers and validates such biology day in and day out.
@Precigenetics
Triple digits ๐ฏ
Electron has reached 100 launches faster than any commercially developed rocket in history. With another 100+ launches in backlog, we're just getting started.